195 related articles for article (PubMed ID: 16404704)
1. Effect of hirudin versus heparin on hemocompatibility of blood contacting biomaterials: an in vitro study.
Kopp R; Bernsberg R; Kashefi A; Mottaghy K; Rossaint R; Kuhlen R
Int J Artif Organs; 2005 Dec; 28(12):1272-7. PubMed ID: 16404704
[TBL] [Abstract][Full Text] [Related]
2. Effects of recombinant hirudin (r-hirudin, HBW 023) on coagulation and platelet activation in vivo. Comparison with unfractionated heparin and a low-molecular-weight heparin preparation (fragmin).
Eichinger S; Wolzt M; Schneider B; Nieszpaur-Los M; Heinrichs H; Lechner K; Eichler HG; Kyrle PA
Arterioscler Thromb Vasc Biol; 1995 Jul; 15(7):886-92. PubMed ID: 7600120
[TBL] [Abstract][Full Text] [Related]
3. Surface-bound heparin fails to reduce thrombin formation during clinical cardiopulmonary bypass.
Gorman RC; Ziats N; Rao AK; Gikakis N; Sun L; Khan MM; Stenach N; Sapatnekar S; Chouhan V; Gorman JH; Niewiarowski S; Colman RW; Anderson JM; Edmunds LH
J Thorac Cardiovasc Surg; 1996 Jan; 111(1):1-11; discussion 11-2. PubMed ID: 8551753
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of coagulation and thrombin-induced platelet activities by a synthetic dodecapeptide modeled on the carboxy-terminus of hirudin.
Jakubowski JA; Maraganore JM
Blood; 1990 Jan; 75(2):399-406. PubMed ID: 2294999
[TBL] [Abstract][Full Text] [Related]
5. Influence of heparin, heparin plus aprotinin and hirudin on contact activation in a cardiopulmonary bypass model.
Wendel HP; Heller W; Gallimore MJ
Immunopharmacology; 1996 May; 32(1-3):57-61. PubMed ID: 8796267
[TBL] [Abstract][Full Text] [Related]
6. Reactivation of coagulation after stopping infusions of recombinant hirudin and unfractionated heparin in unstable angina and myocardial infarction without ST elevation: results of a randomized trial. OASIS Pilot Study Investigators. Organization to Assess Strategies for Ischemic++ Syndromes.
Flather MD; Weitz JI; Yusuf S; Pogue J; Sussex B; Campeau J; Gill J; Schuld R; Joyner CD; Morris AL; Lai C; Théroux P; Marquis JF; Chan YK; Venkatesh G; Jessel A
Eur Heart J; 2000 Sep; 21(17):1473-81. PubMed ID: 10952840
[TBL] [Abstract][Full Text] [Related]
7. Recombinant hirudin as an anticoagulant during cardiac operations: experiments in a pig model.
Riess FC; Pötzsch B; Behr I; Jäger K; Rössing R; Bleese N; Schaper W; Müller-Berghaus G
Eur J Cardiothorac Surg; 1997 Apr; 11(4):739-45. PubMed ID: 9151047
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the antithrombotic effect of PEG-hirudin and heparin in a human ex vivo model of arterial thrombosis.
Bossavy JP; Sakariassen KS; Rübsamen K; Thalamas C; Boneu B; Cadroy Y
Arterioscler Thromb Vasc Biol; 1999 May; 19(5):1348-53. PubMed ID: 10323789
[TBL] [Abstract][Full Text] [Related]
9. The relationship between hirudin and activated clotting time: implications for patients with heparin-induced thrombocytopenia undergoing cardiac surgery.
Despotis GJ; Hogue CW; Saleem R; Bigham M; Skubas N; Apostolidou I; Qayum A; Joist JH
Anesth Analg; 2001 Jul; 93(1):28-32. PubMed ID: 11429333
[TBL] [Abstract][Full Text] [Related]
10. Future alternatives to heparin: low-molecular-weight heparin and hirudin.
Donayre CE; Ouriel K; Rhee RY; Shortell CK
J Vasc Surg; 1992 Apr; 15(4):675-82. PubMed ID: 1313932
[TBL] [Abstract][Full Text] [Related]
11. Recombinant hirudin as a periprocedural antithrombotic in coronary angioplasty for unstable angina pectoris.
Hafner G; Rupprecht HJ; Luz M; Terres W; Schindel F; Friesen HJ; Heinrichs H; Jessel A; Meyer J; Prellwitz W
Eur Heart J; 1996 Aug; 17(8):1207-15. PubMed ID: 8869862
[TBL] [Abstract][Full Text] [Related]
12. r-Hirudin inhibits platelet-dependent thrombosis during cardiopulmonary bypass in baboons.
van Wyk V; Neethling WM; Badenhorst PN; Kotzé HF
J Cardiovasc Surg (Torino); 1998 Oct; 39(5):633-9. PubMed ID: 9833724
[TBL] [Abstract][Full Text] [Related]
13. Effect of hirudin vs heparin on haemostatic activity in patients with acute coronary syndromes; the GUSTO-IIb haemostasis substudy.
Kottke-Marchant K; Bahit MC; Granger CB; Zoldhelyi P; Ardissino D; Brooks L; Griffin JH; Potthoff RF; Van de Werf F; Califf RM; Topol EJ
Eur Heart J; 2002 Aug; 23(15):1202-12. PubMed ID: 12127922
[TBL] [Abstract][Full Text] [Related]
14. The effect of r-hirudin vs. heparin on blood-membrane interactions during hemodialysis.
van Wyk V; Badenhorst PN; Kotzé HF
Clin Nephrol; 1997 Dec; 48(6):381-7. PubMed ID: 9438098
[TBL] [Abstract][Full Text] [Related]
15. Higher concentrations of heparin and hirudin are required to inhibit thrombin generation in tissue factor-activated cord plasma than in adult plasma.
Baier K; Cvirn G; Fritsch P; Köstenberger M; Gallistl S; Leschnik B; Muntean W
Pediatr Res; 2005 May; 57(5 Pt 1):685-9. PubMed ID: 15718352
[TBL] [Abstract][Full Text] [Related]
16. Hirudin versus heparin for use in whole blood in vitro biocompatibility models.
Bexborn F; Engberg AE; Sandholm K; Mollnes TE; Hong J; Nilsson Ekdahl K
J Biomed Mater Res A; 2009 Jun; 89(4):951-9. PubMed ID: 18470919
[TBL] [Abstract][Full Text] [Related]
17. Laboratory assays for the evaluation of recombinant hirudin.
Walenga JM; Hoppensteadt D; Koza M; Wallock M; Pifarre R; Fareed J
Haemostasis; 1991; 21 Suppl 1():49-63. PubMed ID: 1894197
[TBL] [Abstract][Full Text] [Related]
18. Delayed thrombin generation with hirudin anticoagulation during prolonged cardiopulmonary bypass.
Rubens FD; Lavalee G; Ruel MA; Mesana T; Bourke M
Ann Thorac Surg; 2005 Jan; 79(1):334-6. PubMed ID: 15620975
[TBL] [Abstract][Full Text] [Related]
19. Cell activation and thrombin generation in heparin bonded cardiopulmonary bypass circuits using a novel in vitro model.
Bannan S; Danby A; Cowan D; Ashraf S; Gesinde M; Martin P
Eur J Cardiothorac Surg; 1997 Aug; 12(2):268-75. PubMed ID: 9288518
[TBL] [Abstract][Full Text] [Related]
20. The significance of TFPI in clotting assays--comparison and combination with other anticoagulants.
Nordfang O; Kristensen HI; Valentin S; Ostergaard P; Wadt J
Thromb Haemost; 1993 Sep; 70(3):448-53. PubMed ID: 8259547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
